Jylamvo - Europe

Jylamvo is an oral solution that contains 2 mg/ml of methotrexate. The product was granted a European Marketing Authorisation by the European Medicines Agency (EMA) on 29 March 2017.

Jylamvo is authorised for use in the following indications:

In rheumatological and dermatological diseases

  • Active rheumatoid arthritis in adult patients.

  • Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non‑steroidal anti‑inflammatory drugs (NSAIDs) has been inadequate.

  • Severe, treatment‑refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.


In oncology

  • Maintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over 


For Medical Information, Product Complaints, Adverse Event Reporting, please click here.

For Sales inquires, please click here

Educational Package for Healthcare Professionals, please click here.